Literature DB >> 9733383

Intra-articular empyema due to Staphylococcus caprae following arthroscopic cruciate ligament repair.

H A Elsner1, G P Dahmen, R Laufs, D Mack.   

Abstract

Staphylococcus caprae is a catalase-positive, coagulase-negative coccus that has been originally isolated from goat milk. We describe the first case of an intra-articular empyema caused by S. caprae in an immunocompetent patient following arthroscopic cruciate ligament repair. The patient recovered completely after debridement and antibiotic therapy with cefazolin and amoxicillin, respectively. This case demonstrates that this organism may rarely cause serious nosocomial infections in immunocompetent adults.

Entities:  

Mesh:

Year:  1998        PMID: 9733383     DOI: 10.1016/s0163-4453(98)90733-2

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  4 in total

1.  Central line-associated bacteremia caused by drug-resistant Staphylococcus caprae after chemotherapy for acute myelogenous leukemia.

Authors:  Jun Kato; Takehiko Mori; Kayoko Sugita; Mitsuru Murata; Yukako Ono; Akiko Yamane; Takayuki Shimizu; Shinichiro Okamoto
Journal:  Int J Hematol       Date:  2010-06       Impact factor: 2.490

2.  Report of a strain of Staphylococcus caprae with the genes for enterotoxin A and enterotoxin-like toxin type P.

Authors:  Dawn Weir; Crosby Jones; Loren Ammerman; Kim Dybdahl; Suzanne Tomlinson
Journal:  J Clin Microbiol       Date:  2007-08-01       Impact factor: 5.948

3.  Staphylococcus caprae strains carry determinants known to be involved in pathogenicity: a gene encoding an autolysin-binding fibronectin and the ica operon involved in biofilm formation.

Authors:  J Allignet; S Aubert; K G Dyke; N El Solh
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

4.  Methicillin-resistant Staphylococcus caprae in a neonatal intensive care unit.

Authors:  T L Ross; E P Fuss; S M Harrington; M Cai; T M Perl; W G Merz
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.